Questions regarding the optimal use of bevacizumab in glioblastoma:  a moving target.
Roger
R
Stupp
Michael
M
Weller
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy*; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab